Skip to content
ESSA Pharma
  • Our Company
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisors
    • Careers
  • Pipeline
    • Pipeline
    • Expanded Access Policy
    • Androgen Receptor
    • Aniten Compounds
    • Publications
  • News
  • Investors
    • Investor Info
    • Corporate Governance
    • Events & Presentations
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Investor Contact
    • Publications
    • SEC Regulatory Filings
  • Contact
ESSA PHARMA, INC. HAS BEGUN DEVELOPMENT OF A SECOND GENERATION ANITEN COMPOUND FOR THE TREATMENT OF HORMONE-DRIVEN CANCER

News

News Archives

  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
Date Title
January 13, 2021

ESSA Pharma Announces Clinical Collaboration with Janssen to Evaluate EPI-7386 Combination for Patients with Metastatic Castration-Resistant Prostate Cancer

  • Home
  • Our Company
  • Executive Team
  • Board of Directors
  • Scientific Advisors
  • Careers
  • Pipeline
  • Expanded Access Policy
  • Androgen Receptor
  • Aniten Compounds
  • Publications
  • News
  • Press Releases
  • Investors
  • Corporate Governance
  • Events & Presentations
  • Financial Information
  • Stock Information
  • Analyst Coverage
  • Investor Contact
  • Contact
  • Locations & Inquiries
© ESSA Pharma, Inc. 2020. All rights reserved. Privacy Policy | Terms & Conditions | Code of Conduct